Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe

Executive Summary

German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.

You may also be interested in...



Germany's Stada Strengthens Central, Eastern European Focus With Brand, Generic Buys

Stada spends $537 million on Grünenthal's branded product portfolio in Central and Eastern Europe and Spirig's generics business in Switzerland.

AstraZeneca’s Real-World Outcomes Deal With IMS Aims To Turn Treatment Data Into Business Decisions

Accessing IMS Health’s European electronic health records and jointly building a customized data analysis platform will inform AstraZeneca’s R&D priorities and support outcomes claims of newly-launched drugs.

FDA Retains Personal Touch In Monitoring Drug Promotions

Based on a sales rep’s comments overheard at a pharmacist meeting, FDA warns Ortho-McNeil-Janssen about making unsubstantiated claims for pain killer Nucynta. The general pain relief claim granted the drug does not qualify it for use in the chronic pain condition discussed by the sales rep, FDA says.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054064

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel